Yarbrough Capital’s Edwards Lifesciences EW Stock Holding History

Yarbrough Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,776	Closed	-$361K	–	199
2024 Q1	$361K	Hold	3,776	–	–	0.02%	169
2023 Q4	$288K	Hold	3,776	–	–	0.02%	183
2023 Q3	$262K	Hold	3,776	–	–	0.02%	188
2023 Q2	$356K	Hold	3,776	–	–	0.02%	166
2023 Q1	$312K	Sell	3,776 -2,000	-35%	-$157K	0.03%	172
2022 Q4	$431K	Hold	5,776	–	–	0.03%	110
2022 Q3	$477K	Hold	5,776	–	–	0.04%	114
2022 Q2	$549K	Buy	+5,776	New	+$598K	0.04%	103

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Yarbrough Capital's EW Position: Q2 2024 in Review

Yarbrough Capital sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 3,776 shares — an estimated $361K sold.

Yarbrough Capital first reported a position in EW in Q2 2022 and held it in 8 quarters. The position peaked at $549K in Q2 2022. 1,296 funds tracked by Wall St. Rank hold EW as of Q2 2024.

Yarbrough Capital reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
Yarbrough Capital sold 3,776 Edwards Lifesciences shares in Q2 2024, an estimated $361K.
Yarbrough Capital first reported a position in Edwards Lifesciences in Q2 2022 and held it in 8 quarters.
Yarbrough Capital's Edwards Lifesciences position peaked at $549K in Q2 2022.
1,296 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.

Based on Yarbrough Capital's 13F filing for Q2 2024, filed 17 Jul 2024.